BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:Fleming : AI-driven Integrated Drug Discovery Platform
DTSTART;VALUE=DATE-TIME:20191107T051000Z
DTEND;VALUE=DATE-TIME:20191107T053000Z
DTSTAMP;VALUE=DATE-TIME:20260724T113236Z
UID:indico-contribution-30@sshep.snu.ac.kr
DESCRIPTION:Speakers: Junsu Ko (© Arontier)\nNew drug development cost mo
 re than one billion over the last decade. And the chance of success was qu
 ite low\, one in five thousands. In order to make the drug development pro
 cess efficient in terms of time and cost\, Artificial Intelligence has bee
 n actively introduced to and rigorously adopted in the various fields of d
 rug development: compound activity prediction\, compound design\, patient 
 selection\, and clinical trial design\, just to name a few.\n\nAs these fi
 elds become advanced\, more AI-based drug development platforms are develo
 ped and deployed in the fields to overcome data shortage.\n\nFleming is an
  integrated and automated platform for time and cost efficient drug develo
 pment. It uses protein structure prediction and genome-based target select
 ion for efficiency. In Fleming\, precise target protein structures\, gener
 ated by protein structure prediction techniques using AI\, are used to pic
 k candidate compounds and to design active compounds with high chance of s
 uccess. And genome-based analysis powered by Fleming AI selects (find-an-a
 djective-for-this) compounds by predicting compound activity and toxicity.
 \n\nThese features in Fleming accelerate the new drug development process 
 utilizing and combining various technologies: disease genome analysis\, ca
 ndidate compound selection\, compound generation\, activity prediction\, a
 nd toxicity prediction.\n\nhttps://sshep.snu.ac.kr/event/107/contributions
 /30/
LOCATION:Seoul National University\, College of Natural Sciences\, Buildin
 g 25-1 국제회의실 (International Conference Hall)
URL:https://sshep.snu.ac.kr/event/107/contributions/30/
END:VEVENT
END:VCALENDAR